The Clinical Referral to Activity Study

June 7, 2023 updated by: Bonny Rockette-Wagner, University of Pittsburgh

Advancement of Clinical Referral to Physical Activity for Cardiometabolic Disease Prevention

The main aim of this effort is to test a physical activity intervention, for adult clinical care patients at risk of developing cardiovascular disease. The intervention includes social-cognitive theory-based sessions, remote coaching, a body worn physical activity tracker (PAT), and is delivered online over one year. The investigators hypothesis that this intervention will be more successful at increasing physical activity (defined as objectively measured step counts and % of individuals meeting the moderate-vigorous physical activity goal) as an active control group who receives a body worn PAT and information on the CDC activity recommendations. The proposed intervention will be aligned with efforts by the US Centers for Disease Control to increase population physical activity levels and the American College of Sports Medicine (ACSM) to increase physical activity prescription in primary care.

Study Overview

Detailed Description

The main aim of this effort is to test a physical activity intervention, for adult clinical care patients at risk of developing cardiovascular disease. The intervention includes 13 weekly and 6 monthly social-cognitive theory-based sessions, remote coaching, a body worn physical activity tracker (PAT), and is delivered online over one year.

A total of n=54 Clinical care patients aged 40-70 years of age with low physical activity (PA) levels (<150 minutes/week) at risk for cardiovascular disease will be recruited. Study outcomes will be measured at baseline, 6 months after intervention start and 12 months after intervention start.

For the primary outcomes, the investigators hypothesize that participants randomized to ActiveGOALSv2 + PAT will have significantly larger (a) increases in step counts/day and % meeting moderate-vigorous physical activity goal of 150 minutes/week (to 12 months) compared to the active PAT control group. Descriptive analyses and graphic displays will be used to identify outliers, missing data, and pattern of attrition. To ensure rigor, the primary analytic strategy will be a linear or generalized mixed-effect models approach in which treatment group, time, and time by group interaction are treated as fixed effects, and subject is treated as a random effect to account for individual subject variability (two sided hypothesis test; .05 level). Mixed models are applicable to longitudinal datasets that contain missing observations, (assuming data is missing at random). Regression modeling will be conducted to adjust for important covariates. The investigators will perform similar analyses to examine changes in secondary outcomes. Descriptive statistics on patient experience, beliefs/attitudes related to maintenance of physical activity changes, and program cost will also be reported.

Power and sample size: For a 2 sided test with alpha level set at .05, and assuming 20% attrition at 12 months, the investigators plan to recruit 54 participants to identify clinically relevant mean difference between randomized groups at 12-months of 2000 steps/day (with a power of .80), and 35% meeting MVPA goal (with a power of .80), given reference mean (sd) values were calculated from baseline waist worn accelerometer data from the current K12 of: 5250 (2200) steps/ day and the investigators assume 5% meeting goal at baseline in the control group.

Descriptive statistics will be used to describe the total eligible population, those referred, and those referred who participated in the study; in order to determine program reach. Exploratory Analysis of Important Pre-Existing Factors: Factor analysis will be used to identify importance of factors related to physical activity levels/ activity goal achievement over the 12 month follow-up (Mplus) from participant EHR data collected prior to intervention start. Factor structures of how individual factors contribute to activity outcomes will be explored at each time point. The best factor structure will be determined with Eigenvalues and fit indices (RMSEA, CFI, and TLI). Factor structures at the 2 time points will be compared at three levels to establish measurement invariance: 1) Configural equivalence, number of factors/ pattern of factor-indicator relationships are identical over time; 2) Metric equivalence, factor loadings are equal over time; and 3) Scalar equivalence, means and values are equivalent over time. Finally, the investigators will use descriptive statistics to report presence/absence of data on physical activity levels, cardiometabolic, and patient-centered outcomes in the EHR. The investigators will apply the same regression approaches utilized in Aim 1a to determine differences between randomized groups for EHR reported outcomes.

Study Type

Interventional

Enrollment (Estimated)

54

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Bonny Rockette-Wagner, PhD
  • Phone Number: (412) 624-0118
  • Email: bjr26@pitt.edu

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15261
        • Recruiting
        • University of Pittsburgh
        • Contact:
          • Bonny Rockette-Wagner, PhD
          • Phone Number: 412-624-0188
          • Email: bjr26@pitt.edu

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Age 40-70 years of age
  • Low physical activity (PA) levels (<150 minutes/week)
  • At least one of the following common cardiometabolic risk factors:

    • high blood pressure:> 129 mm hg SP or >89 mm hg DP or medication
    • high fasting glucose:>100 mg/dl or high HbA1c: ≥42 mmols/mol or medication
    • overweight/ obesity: BMI ≥25 kg/m2).
  • Have access to the internet
  • Able to read English at a 6th grade level
  • Have primary care provider (PCP) permission to increase physical activity without supervision.

Exclusion Criteria:

  • Have participated in a physical activity intervention program with behavior tracking and goal setting in the past year.
  • Told by a physician that they have diabetes (other than previous gestational diabetes) or have received a diagnosis of cardiovascular disease, regardless of when.
  • Pregnant or planning a pregnancy in <12 months
  • Non-ambulatory or planning a procedure that will lead to not being ambulatory in <12 months.
  • Women who become pregnant during the study will be required to get an updated referral form from their primary care provider (PCP) stating that they are able to increase their physical activity without supervision .

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: PAT (Physical activity monitor)
Participants will receive a physical activity tracker and encouragement to increase physical activity.
Participants will receive a physical activity tracker and encouragement to increase activity.
Experimental: ActiveGOALSv2
Participants will receive the ActiveGOALS online program with an integrated activity tracker.
13 weekly self-guided sessions on problem solving and goal setting related to increasing physical activity, and weekly remote coaching support. Once a month support materials sent monthly from months 4-12 of intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline in meeting the aerobic activity goal at 12 months
Time Frame: 12 months versus baseline
Change between 0 and 12 months for y/n meeting the 150 minute/week moderate-vigorous activity goal based on minutes of activity from accelerometer
12 months versus baseline
Change from baseline in Step counts at 12 months
Time Frame: 12 months versus baseline
Objectively measured change in step counts between 0 and 12 months using ActiGraph accelerometer
12 months versus baseline

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sedentary behavior minutes over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
Objectively measured sedentary behavior over all timepoints for 12 months using ActiGraph accelerometer
1 week recording; measured at baseline, 6 and 12 months
Moderate-vigorous activity minutes over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
Objectively measured moderate-vigorous activity over all timepoints for 12 months using ActiGraph accelerometer
1 week recording; measured at baseline, 6 and 12 months
Light activity minutes over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
Objectively measured Light activity over all timepoints for 12 months using ActiGraph accelerometer
1 week recording; measured at baseline, 6 and 12 months
Step counts over all timepoints for 12 months
Time Frame: 1 week recording; measured at baseline, 6 and 12 months
Objectively measured Step counts over all timepoints for 12 months using ActiGraph accelerometer
1 week recording; measured at baseline, 6 and 12 months
Patient experience
Time Frame: measured at 6 and 12 months
patient experience survey designed for this study with the help of patient partners to gather feedback from participants. Feedback will be used in the development of future interventions
measured at 6 and 12 months
Blood Pressure over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
Taken by trained clinic staff using a validated automated blood pressure cuff after participant is seated in an upright position for 5 minutes. Two measure will be taken and the average of the two measures will be used. If the measures are not within 5 mmHG, a third measure will be taken.
measured at baseline, 6 and 12 months
Body Weight over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
will be measured in clinic by trained staff using a validated scale. Participants will be asked to take shoes off and wear light clothes. Average of two measures will be used; if weight is more than .5 pounds different, a third will be taken.
measured at baseline, 6 and 12 months
Waist Circumference over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
will be measured above the iliac crest in clinic by trained staff. Two measures will be taken and averaged; if measures are more than 1 cm different a third measure will be taken.
measured at baseline, 6 and 12 months
Fasting Blood Glucose over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
A fasting blood draw will be taken after 12-16 hours fast.
measured at baseline, 6 and 12 months
HbA1c over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
A fasting blood draw will be taken after 12-16 hours fast.
measured at baseline, 6 and 12 months
LDL Cholesterol over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
A fasting blood draw will be taken after 12-16 hours fast.
measured at baseline, 6 and 12 months
HDL Cholesterol over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
A fasting blood draw will be taken after 12-16 hours fast.
measured at baseline, 6 and 12 months
Perceived Health Score over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
EuroQAL Visual Analogue Scale (EQ-VAS)-Self-reported perception of health on a 0 (lowest possible) to 100 (highest possible) scale.
measured at baseline, 6 and 12 months
Insulin over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
A fasting blood draw will be taken after 12-16 hours fast.
measured at baseline, 6 and 12 months
Triglycerides over all timepoints for 12 months
Time Frame: measured at baseline, 6 and 12 months
A fasting blood draw will be taken after 12-16 hours fast.
measured at baseline, 6 and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bonny Rockette-Wagner, PhD, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 29, 2022

Primary Completion (Estimated)

May 31, 2024

Study Completion (Estimated)

May 31, 2024

Study Registration Dates

First Submitted

January 10, 2021

First Submitted That Met QC Criteria

February 3, 2021

First Posted (Actual)

February 8, 2021

Study Record Updates

Last Update Posted (Actual)

June 9, 2023

Last Update Submitted That Met QC Criteria

June 7, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • STUDY20030079
  • 1K01HL151668-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on PAT

3
Subscribe